HRP20110193T1 - Inhibitor hcv nukleozida - Google Patents
Inhibitor hcv nukleozida Download PDFInfo
- Publication number
- HRP20110193T1 HRP20110193T1 HR20110193T HRP20110193T HRP20110193T1 HR P20110193 T1 HRP20110193 T1 HR P20110193T1 HR 20110193 T HR20110193 T HR 20110193T HR P20110193 T HRP20110193 T HR P20110193T HR P20110193 T1 HRP20110193 T1 HR P20110193T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- group
- hydrogen
- hcv
- methyl
- Prior art date
Links
- 239000002777 nucleoside Substances 0.000 title claims 3
- 150000003833 nucleoside derivatives Chemical class 0.000 title claims 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 11
- 239000001257 hydrogen Substances 0.000 claims abstract 11
- 150000002431 hydrogen Chemical class 0.000 claims abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract 5
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 claims abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 150000002367 halogens Chemical group 0.000 claims abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 2
- KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims abstract 2
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 2
- 239000001177 diphosphate Substances 0.000 claims abstract 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims abstract 2
- 235000011180 diphosphates Nutrition 0.000 claims abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims abstract 2
- 150000004712 monophosphates Chemical class 0.000 claims abstract 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims abstract 2
- 239000001226 triphosphate Substances 0.000 claims abstract 2
- 235000011178 triphosphate Nutrition 0.000 claims abstract 2
- -1 triphosphate ester Chemical class 0.000 claims abstract 2
- 241000711549 Hepacivirus C Species 0.000 claims 8
- 101100295741 Gallus gallus COR4 gene Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 229940122604 HCV protease inhibitor Drugs 0.000 claims 1
- 229940121759 Helicase inhibitor Drugs 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- 229940122488 Primase inhibitor Drugs 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229940125777 fusion inhibitor Drugs 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85092606P | 2006-10-10 | 2006-10-10 | |
| PCT/EP2007/060557 WO2008043704A1 (en) | 2006-10-10 | 2007-10-04 | Hcv nucleoside inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110193T1 true HRP20110193T1 (hr) | 2011-05-31 |
Family
ID=38925483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110193T HRP20110193T1 (hr) | 2006-10-10 | 2011-03-16 | Inhibitor hcv nukleozida |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US7666856B2 (no) |
| EP (2) | EP2084175B1 (no) |
| JP (2) | JP2010505902A (no) |
| KR (1) | KR20090078347A (no) |
| CN (2) | CN101979397B (no) |
| AP (1) | AP2009004812A0 (no) |
| AT (1) | ATE493428T1 (no) |
| AU (1) | AU2007306405A1 (no) |
| BR (1) | BRPI0719258A2 (no) |
| CA (1) | CA2665049C (no) |
| CO (1) | CO6180441A2 (no) |
| CR (1) | CR10789A (no) |
| CY (1) | CY1111342T1 (no) |
| DE (1) | DE602007011658D1 (no) |
| DK (1) | DK2084175T3 (no) |
| EA (1) | EA018935B1 (no) |
| ES (2) | ES2392948T3 (no) |
| GT (1) | GT200900069A (no) |
| HK (2) | HK1137459A1 (no) |
| HN (1) | HN2009000614A (no) |
| HR (1) | HRP20110193T1 (no) |
| IL (1) | IL197907A0 (no) |
| MX (1) | MX2009003452A (no) |
| MY (1) | MY145314A (no) |
| NO (1) | NO20091834L (no) |
| NZ (1) | NZ575889A (no) |
| PL (2) | PL2361922T3 (no) |
| PT (1) | PT2084175E (no) |
| RS (1) | RS51643B (no) |
| SI (1) | SI2084175T1 (no) |
| WO (1) | WO2008043704A1 (no) |
| ZA (1) | ZA200902496B (no) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2084175T3 (da) * | 2006-10-10 | 2011-04-18 | Medivir Ab | HCV nucleosidinhibitor |
| CN100532388C (zh) * | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
| US20090318380A1 (en) * | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| AR072428A1 (es) * | 2008-07-01 | 2010-08-25 | Medivir Ab | Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos. |
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| EP2166016A1 (en) | 2008-09-18 | 2010-03-24 | Centocor Ortho Biotech Products L.P. | Phosphoramidate Derivatives of Nucleosides |
| TW201023858A (en) * | 2008-09-18 | 2010-07-01 | Ortho Mcneil Janssen Pharm | Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside |
| PA8852101A1 (es) | 2008-12-08 | 2010-07-27 | Medivir Ab | Nucleótidos uracil ciclopropílicos |
| DE102009028015A1 (de) * | 2009-07-24 | 2011-01-27 | Virologik Gmbh | Mittel zur Behandlung von Hepatitis C-Infektionen |
| RU2553656C2 (ru) | 2009-09-29 | 2015-06-20 | ЯНССЕН ПРОДАКТС, Эл.Пи. | Фосфорамидатные производные нуклеозидов |
| JP5989635B2 (ja) | 2010-04-13 | 2016-09-07 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | Ｈｃｖの大環状阻害剤、非ヌクレオシドおよびヌクレオシドの組合せ |
| MX2013003153A (es) | 2010-09-22 | 2013-05-01 | Alios Biopharma Inc | Analogos de nucleotidos sustituidos. |
| US8877731B2 (en) | 2010-09-22 | 2014-11-04 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013056046A1 (en) | 2011-10-14 | 2013-04-18 | Idenix Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| WO2013142124A1 (en) | 2012-03-21 | 2013-09-26 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
| US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| AP3913A (en) | 2012-05-22 | 2016-11-26 | Idenix Pharamaceuticals Inc | D-amino acid compounds for liver disease |
| EP2861611B1 (en) | 2012-05-25 | 2016-07-13 | Janssen Sciences Ireland UC | Uracyl spirooxetane nucleosides |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| EA030189B8 (ru) | 2012-10-08 | 2018-10-31 | Иденикс Фармасьютикалз Ллс | Аналоги 2'-хлоронуклеозидов для инфекции вгс |
| US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| RS61767B1 (sr) * | 2012-12-21 | 2021-05-31 | Janssen Biopharma Inc | 4'-fluor-nukleozidi, 4'-fluor-nukleotidi i njihovi analozi za lečenje hcv |
| US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
| US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
| WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
| WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
| EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| UA117375C2 (uk) * | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6339752A (ja) | 1986-08-02 | 1988-02-20 | Kawada Tekko Kk | インデツクス装置 |
| SE8701605D0 (sv) | 1987-04-16 | 1987-04-16 | Astra Ab | Novel medicinal compounds |
| DE3715666A1 (de) | 1987-05-11 | 1988-11-24 | Kodak Ag | Kassettenentlade- und beladegeraet |
| GB8712115D0 (en) | 1987-05-22 | 1987-06-24 | Hoffmann La Roche | Pyrimidine derivatives |
| US5246924A (en) | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
| SE8802173D0 (sv) | 1988-06-10 | 1988-06-10 | Astra Ab | Pyrimidine derivatives |
| SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
| EP0371366A1 (en) * | 1988-11-21 | 1990-06-06 | Syntex (U.S.A.) Inc. | Antiviral agents |
| US5034518A (en) | 1989-05-23 | 1991-07-23 | Southern Research Institute | 2-fluoro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine nucleosides |
| CA2055460C (en) | 1990-03-30 | 1997-04-01 | Neil Warren Boaz | Alcohol-ester separation by reaction with acetate |
| AU7623991A (en) * | 1990-05-17 | 1991-11-21 | Syntex (U.S.A.) Inc. | Antiviral agents |
| IT1249732B (it) | 1991-11-26 | 1995-03-09 | Angeletti P Ist Richerche Bio | Oligonucleotidi antisenso. |
| US5418151A (en) | 1992-08-07 | 1995-05-23 | Genencor International, Inc. | Regio-selective process for resolution of carbohydrate monoesters |
| US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
| AU2787199A (en) | 1998-02-25 | 1999-09-15 | Emory University | 2'-fluoronucleosides |
| US6492423B1 (en) | 1998-07-27 | 2002-12-10 | Istituto Di Ricerche Di Biologia Molecolare Pangeletti Spa | Diketoacid-derivatives as inhibitors of polymerases |
| ID27787A (id) | 1998-08-21 | 2001-04-26 | Viro Pharma Inc | Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan |
| JP2002524423A (ja) | 1998-09-04 | 2002-08-06 | バイロファーマ・インコーポレイテッド | ウイルス感染および関連疾患の治療および予防方法 |
| AU751457B2 (en) | 1998-09-25 | 2002-08-15 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
| WO2000069876A1 (en) | 1999-05-12 | 2000-11-23 | Yamasa Corporation | 4'-c-ethynyl pyrimidine nucleosides |
| WO2001032153A2 (en) | 1999-11-04 | 2001-05-10 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| JP3373502B2 (ja) | 1999-12-24 | 2003-02-04 | 旭硝子株式会社 | 窒化ケイ素フィルタおよびその製造法 |
| WO2001077091A2 (en) | 2000-04-05 | 2001-10-18 | Tularik Inc. | Ns5b hcv polymerase inhibitors |
| AU2001261377A1 (en) | 2000-05-10 | 2001-11-20 | Smith Kline Beecham Corporation | Novel anti-infectives |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| EA200601591A1 (ru) | 2000-05-26 | 2007-02-27 | Айденикс (Кайман) Лимитед | Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| WO2002005787A1 (fr) | 2000-07-17 | 2002-01-24 | Takeda Chemical Industries, Ltd. | Fabrication pour produits lyophilises |
| GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| AU2002243791B2 (en) | 2001-01-22 | 2006-06-29 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| US6677120B2 (en) | 2001-03-30 | 2004-01-13 | Isis Pharmaceuticals, Inc. | Building blocks for the solution phase synthesis of oligonucleotides |
| KR100798579B1 (ko) | 2001-03-31 | 2008-01-28 | 동화약품공업주식회사 | 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물 |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| US6881741B2 (en) | 2001-06-11 | 2005-04-19 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
| GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| WO2003007945A1 (en) | 2001-07-20 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| US6899700B2 (en) | 2001-08-29 | 2005-05-31 | Kimberly-Clark Worldwide, Inc. | Therapeutic agent delivery tampon |
| EP1438054A4 (en) | 2001-09-28 | 2006-07-26 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION |
| US7138376B2 (en) | 2001-09-28 | 2006-11-21 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
| AU2002359320A1 (en) | 2001-10-29 | 2003-05-12 | Smithkline Beecham Corporation | Novel anit-infectives |
| WO2003059356A2 (en) | 2001-10-30 | 2003-07-24 | Smithkline Beecham Corporation | Novel anti-infectives |
| WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
| AU2002361518A1 (en) | 2001-12-18 | 2003-06-30 | Gustavo Fernandez Del Castillo Y Simon | Column-type multi-piston |
| US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| WO2003099801A1 (en) | 2002-05-24 | 2003-12-04 | Smithkline Beecham Corporation | Novel anti-infectives |
| BR0312271A (pt) | 2002-06-28 | 2007-11-06 | Idenix Cayman Ltd | compostos, composições e seus usos para o tratamento de infecções por flaviviridae |
| BR0312278A (pt) | 2002-06-28 | 2007-06-19 | Idenix Cayman Ltd | éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae |
| MXPA04012779A (es) | 2002-06-28 | 2005-08-19 | Idenix Cayman Ltd | Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae. |
| US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| CA2504385C (en) | 2002-11-01 | 2012-12-18 | Abbott Laboratories | Thiadiazine compounds and uses thereof |
| NO319194B1 (no) | 2002-11-14 | 2005-06-27 | Pronova Biocare As | Lipase-katalysert forestringsfremgangsmate av marine oljer |
| DK1576138T3 (en) | 2002-11-15 | 2017-05-01 | Idenix Pharmaceuticals Llc | 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION |
| TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| TWI294882B (en) | 2002-12-09 | 2008-03-21 | Hoffmann La Roche | Anhydrous crystalline azido cytosine hemisulfate derivative |
| WO2004052313A2 (en) | 2002-12-11 | 2004-06-24 | Smithkline Beecham Corporation | Anti-infectives |
| AU2003300956A1 (en) | 2002-12-11 | 2004-06-30 | Smithkline Beecham Corporation | Anti-infectives |
| WO2004058150A2 (en) | 2002-12-17 | 2004-07-15 | Smithkline Beecham Corporation | Anti-infectives |
| US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
| MXPA05013452A (es) | 2003-06-19 | 2006-03-09 | Hoffmann La Roche | Proceso para preparar derivados de 4'-azidonucleosido. |
| US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| WO2005019191A2 (en) | 2003-08-25 | 2005-03-03 | Abbott Laboratories | 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c |
| MXPA06003141A (es) | 2003-09-22 | 2006-06-05 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c. |
| BRPI0506945A (pt) | 2004-01-30 | 2007-06-12 | Medivir Ab | inibidores de serina protease ns-3 de hcv |
| JP4624419B2 (ja) | 2004-08-23 | 2011-02-02 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス性へテロ環化合物 |
| CN101044151B (zh) * | 2004-08-23 | 2011-01-19 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4＇-叠氮基-核苷 |
| DK2084175T3 (da) * | 2006-10-10 | 2011-04-18 | Medivir Ab | HCV nucleosidinhibitor |
-
2007
- 2007-10-04 DK DK07820934.3T patent/DK2084175T3/da active
- 2007-10-04 JP JP2009531813A patent/JP2010505902A/ja not_active Ceased
- 2007-10-04 WO PCT/EP2007/060557 patent/WO2008043704A1/en active Application Filing
- 2007-10-04 EP EP07820934A patent/EP2084175B1/en active Active
- 2007-10-04 CA CA2665049A patent/CA2665049C/en not_active Expired - Fee Related
- 2007-10-04 EP EP10196341A patent/EP2361922B1/en active Active
- 2007-10-04 RS RS20110127A patent/RS51643B/en unknown
- 2007-10-04 EA EA200970358A patent/EA018935B1/ru not_active IP Right Cessation
- 2007-10-04 CN CN201010274006XA patent/CN101979397B/zh not_active Expired - Fee Related
- 2007-10-04 PT PT07820934T patent/PT2084175E/pt unknown
- 2007-10-04 NZ NZ575889A patent/NZ575889A/en not_active IP Right Cessation
- 2007-10-04 AU AU2007306405A patent/AU2007306405A1/en not_active Abandoned
- 2007-10-04 KR KR1020097009591A patent/KR20090078347A/ko not_active Application Discontinuation
- 2007-10-04 PL PL10196341T patent/PL2361922T3/pl unknown
- 2007-10-04 AT AT07820934T patent/ATE493428T1/de active
- 2007-10-04 ES ES10196341T patent/ES2392948T3/es active Active
- 2007-10-04 CN CN2007800379054A patent/CN101573370B/zh not_active Expired - Fee Related
- 2007-10-04 AP AP2009004812A patent/AP2009004812A0/xx unknown
- 2007-10-04 SI SI200730544T patent/SI2084175T1/sl unknown
- 2007-10-04 MX MX2009003452A patent/MX2009003452A/es active IP Right Grant
- 2007-10-04 PL PL07820934T patent/PL2084175T3/pl unknown
- 2007-10-04 BR BRPI0719258-4A2A patent/BRPI0719258A2/pt active Search and Examination
- 2007-10-04 DE DE602007011658T patent/DE602007011658D1/de active Active
- 2007-10-04 MY MYPI20091428A patent/MY145314A/en unknown
- 2007-10-04 ES ES07820934T patent/ES2358853T3/es active Active
- 2007-10-10 US US11/973,681 patent/US7666856B2/en not_active Expired - Fee Related
-
2009
- 2009-03-31 GT GT200900069A patent/GT200900069A/es unknown
- 2009-03-31 CO CO09033094A patent/CO6180441A2/es not_active Application Discontinuation
- 2009-04-05 IL IL197907A patent/IL197907A0/en unknown
- 2009-04-09 ZA ZA200902496A patent/ZA200902496B/xx unknown
- 2009-04-13 HN HN2009000614A patent/HN2009000614A/es unknown
- 2009-05-11 NO NO20091834A patent/NO20091834L/no not_active Application Discontinuation
- 2009-05-11 CR CR10789A patent/CR10789A/es not_active Application Discontinuation
-
2010
- 2010-01-20 US US12/690,842 patent/US7825239B2/en not_active Expired - Fee Related
- 2010-01-29 HK HK10101044.2A patent/HK1137459A1/xx not_active IP Right Cessation
- 2010-09-24 US US12/890,538 patent/US7935681B2/en not_active Expired - Fee Related
-
2011
- 2011-03-16 HR HR20110193T patent/HRP20110193T1/hr unknown
- 2011-03-17 CY CY20111100298T patent/CY1111342T1/el unknown
- 2011-03-28 US US13/073,821 patent/US8158779B2/en not_active Expired - Fee Related
- 2011-07-29 JP JP2011167159A patent/JP2011246485A/ja not_active Ceased
- 2011-08-02 HK HK11108019.7A patent/HK1154247A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110193T1 (hr) | Inhibitor hcv nukleozida | |
| AU2018332540B2 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| JP2010505902A5 (no) | ||
| ES2744587T3 (es) | Análogos de N-nucleósido de pirimidina 1-sustituidos para un tratamiento antiviral | |
| JP5578853B2 (ja) | ウイルス感染の治療のための化合物、及び医薬組成物 | |
| ES2745462T3 (es) | Composición que comprende un inhibidor de NS3 proteasa de VHC y un profármaco de fosforamidato de nucleósido de 2'-desoxi-2'fluoro-2'-C-metiluridina | |
| HRP20151075T1 (hr) | Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino) propanoat | |
| ES2524356T3 (es) | Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae | |
| ES2398684T3 (es) | Análogos de carbanucleósido para el tratamiento antiviral | |
| JP2014196336A (ja) | ウイルス感染の治療のための化合物、及び医薬組成物 | |
| RU2012136379A (ru) | 4'-азидонуклеозиды, активные в отношении hcv | |
| HRP20110732T1 (hr) | Antivirusni spojevi | |
| SG171596A1 (en) | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis c virus | |
| EP1656093A2 (en) | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses | |
| HRP20151000T1 (hr) | Antivirusni spojevi | |
| HRP20140370T1 (hr) | 1'-supstituirani-karba-nukleozid prolijekovi za antivirusni tretman | |
| HRP20130971T1 (hr) | Inhibitori virusne polimeraze | |
| CA2445744A1 (en) | Antiviral nucleoside derivatives | |
| HRP20100180T1 (hr) | Novi spoj piridazina i njegova primjena | |
| JP2012517444A (ja) | 抗ウイルス処置のためのカルバ−ヌクレオシドアナログ | |
| DK1104436T3 (da) | Beta-L-2'-deoxy-nukleosider til behandling af hepatitis B-virus | |
| JP2013537905A5 (no) | ||
| Zhou et al. | Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses | |
| ZA200601632B (en) | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | |
| US10307438B2 (en) | Methods of treating hepatitis E viral infection |